CEL-SCI Corp - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CVM American 2836 https://cel-sci.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CEL-SCI Corp

CVM: Parallel Engagement on Four Fronts - Apr 15th, 2024 10:36 am
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology - Mar 19th, 2024 1:00 pm
CEL-SCI Corporation Issues Letter to Shareholders - Mar 6th, 2024 1:45 pm
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results - Feb 15th, 2024 1:00 pm
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock - Feb 13th, 2024 5:00 pm
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock - Feb 9th, 2024 1:30 pm
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug - Feb 6th, 2024 2:00 pm
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® - Jan 31st, 2024 2:00 pm
CVM: Fiscal Year 2023 in Review - Jan 8th, 2024 9:32 am
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments - Dec 22nd, 2023 1:00 pm
CVM: NICE To Have Your Support - Dec 8th, 2023 8:15 am
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer - Dec 4th, 2023 1:30 pm
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock - Nov 20th, 2023 9:15 pm
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock - Nov 16th, 2023 1:30 pm
12 Best Day Trading Stocks To Buy - Nov 9th, 2023 1:52 pm
CVM: Target Population Comes Into Relief - Nov 8th, 2023 10:06 am
CEL-SCI Issues Letter to Shareholders - Oct 30th, 2023 1:20 pm
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals - Oct 24th, 2023 12:00 pm
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023 - Oct 23rd, 2023 1:15 pm
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production - Oct 19th, 2023 12:00 pm